Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
Orphanet J Rare Dis. 2023 Jun 12;18(1):144. doi: 10.1186/s13023-023-02774-7.
Orphanet J Rare Dis. 2023.
PMID: 37308991
Free PMC article.
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W, Palma A, Schuurman A, Simoens S.
Hughes-Wilson W, et al.
Orphanet J Rare Dis. 2012 Sep 26;7:74. doi: 10.1186/1750-1172-7-74.
Orphanet J Rare Dis. 2012.
PMID: 23013790
Free PMC article.
Item in Clipboard
European approval system for advanced therapies: good news for patients and innovators alike.
Hughes-Wilson W, Mackay D.
Hughes-Wilson W, et al.
Regen Med. 2007 Jan;2(1):5-6. doi: 10.2217/17460751.2.1.5.
Regen Med. 2007.
PMID: 17465768
Free article.
No abstract available.
Item in Clipboard
Cite
Cite